Resultados de procura - Matthew D. Hellmann

Limitar resultados
  1. 1
    PD-1/PD-L1 Axis in Lung Cancer

    PD-1/PD-L1 Axis in Lung Cancer por Fernando C. Santini, Matthew D. Hellmann

    Publicado 2018
    Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  2. 2
    Acquired Resistance to Immune Checkpoint Inhibitors

    Acquired Resistance to Immune Checkpoint Inhibitors por Adam J. Schoenfeld, Matthew D. Hellmann

    Publicado 2020
    Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  3. 3
    Chemotherapy remains an essential element of personalized care for persons with lung cancers

    Chemotherapy remains an essential element of personalized care for persons with lung cancers por Matthew D. Hellmann, Bingyu Li, Jamie E. Chaft, Mark G. Kris

    Publicado 2016
    Ligazón do recurso Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  4. 4
    How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer

    How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer por Solange Peters, M. Reck, Egbert F. Smit, Tony Mok, Matthew D. Hellmann

    Publicado 2019
    Ligazón do recurso Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  5. 5
    Opportunistic infections in patients treated with immunotherapy for cancer

    Opportunistic infections in patients treated with immunotherapy for cancer por Chrisann Kyi, Matthew D. Hellmann, Jedd D. Wolchok, Paul B. Chapman, Michael A. Postow

    Publicado 2014
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  6. 6
    Initial Experience With Lung Cancer Resection After Treatment With T-Cell Checkpoint Inhibitors

    Initial Experience With Lung Cancer Resection After Treatment With T-Cell Checkpoint Inhibitors por Jamie E. Chaft, Matthew D. Hellmann, Moises J. Velez, William D. Travis, Valerie W. Rusch

    Publicado 2017
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  7. 7
    Impact of PD-1 Blockade on Severity of COVID-19 in Patients with Lung Cancers

    Impact of PD-1 Blockade on Severity of COVID-19 in Patients with Lung Cancers por Jia Luo, Hira Rizvi, Jacklynn V. Egger, Isabel R. Preeshagul, Jedd D. Wolchok, Matthew D. Hellmann

    Publicado 2020
    Ligazón do recurso
    Carta
    Engadir a favoritos
    Gardado en:
  8. 8
    Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing

    Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing por Helena A. Yu, Maria E. Arcila, Matthew D. Hellmann, Mark G. Kris, Marc Ladanyi, Gregory J. Riely

    Publicado 2014
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  9. 9
    Clinical Characterization of Immunotherapy-Related Pruritus Among Patients Seen in 2 Oncodermatology Clinics

    Clinical Characterization of Immunotherapy-Related Pruritus Among Patients Seen in 2 Oncodermatology Clinics por Gregory S. Phillips, Azael Freites‐Martínez, Jennifer Wu, Donald Chan, Gabriella Fabbrocini, Matthew D. Hellmann, Mario E. Lacouture

    Publicado 2018
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  10. 10
    Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high‐risk patients with diffuse large B‐cell lymphoma

    Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high‐risk patients with diffuse large B‐cell lymphoma por Jeremy S. Abramson, Matthew D. Hellmann, Jeffrey A. Barnes, Peter S. Hammerman, Christiana E. Toomey, Tak Takvorian, Alona Muzikansky, Ephraim P. Hochberg

    Publicado 2010
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  11. 11
    Multiple Resolution Residually Connected Feature Streams for Automatic Lung Tumor Segmentation From CT Images

    Multiple Resolution Residually Connected Feature Streams for Automatic Lung Tumor Segmentation From CT Images por Jue Jiang, Yu‐Chi Hu, Chia‐Ju Liu, Darragh Halpenny, Matthew D. Hellmann, Joseph O. Deasy, G Mageras, Harini Veeraraghavan

    Publicado 2018
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  12. 12
    Prognostic impact of TTF-1 expression in patients with stage IV lung adenocarcinomas

    Prognostic impact of TTF-1 expression in patients with stage IV lung adenocarcinomas por Juliana Schilsky, Ai Ni, Linda S. Ahn, Sutirtha Datta, William D. Travis, Mark G. Kris, Jamie E. Chaft, Natasha Rekhtman, Matthew D. Hellmann

    Publicado 2017
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  13. 13
    Germline HLA landscape does not predict efficacy of pembrolizumab monotherapy across solid tumor types

    Germline HLA landscape does not predict efficacy of pembrolizumab monotherapy across solid tumor types por Aparna Chhibber, Lingkang Huang, Hong Zhang, Jialin Xu, Rǎzvan Cristescu, Xiao Liu, Devan V. Mehrotra, Judong Shen, Peter Shaw, Matthew D. Hellmann, Alexandra Snyder

    Publicado 2022
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  14. 14
    Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas

    Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas por Juliana Eng, Kaitlin M. Woo, Camelia S. Sima, Andrew J. Plodkowski, Matthew D. Hellmann, Jamie E. Chaft, Mark G. Kris, Maria E. Arcila, Marc Ladanyi, Alexander Drilon

    Publicado 2015
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  15. 15
    PS2 CheckMate 227: Nivolumab + Ipilimumab vs Chemotherapy as 1L Treatment for Advanced NSCLC With High Tumor Mutational Burden

    PS2 CheckMate 227: Nivolumab + Ipilimumab vs Chemotherapy as 1L Treatment for Advanced NSCLC With High Tumor Mutational Burden por Clarissa Mathias, Martin Reck, Matthew D. Hellmann, Suresh S. Ramalingam, Julie R. Brahmer, Kenneth J. O’Byrne, Prabhu Bhagavatheeswaran, Faith E. Nathan, Hossein Borghaei, Luis Paz‐Ares

    Publicado 2018
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  16. 16
    Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib

    Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib por Adam J. Schoenfeld, Kathryn C. Arbour, Hira Rizvi, Afsheen Iqbal, Shirish M. Gadgeel, Jeffrey Girshman, Mark G. Kris, Gregory J. Riely, Helena A. Yu, Matthew D. Hellmann

    Publicado 2019
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  17. 17
    Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 Blockade

    Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 Blockade por Tavi Nathanson, Arun Ahuja, Alex Rubinsteyn, Bülent Arman Aksoy, Matthew D. Hellmann, Diana Miao, Eliezer M. Van Allen, Taha Merghoub, Jedd D. Wolchok, Alexandra Snyder, Jeff Hammerbacher

    Publicado 2016
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  18. 18
    Baseline Radiomic Signature to Estimate Overall Survival in Patients With NSCLC

    Baseline Radiomic Signature to Estimate Overall Survival in Patients With NSCLC por Laurent Dercle, Matthew Fronheiser, Naiyer A. Rizvi, Matthew D. Hellmann, Sabine Maier, Wendy Hayes, Hao Yang, Pingzhen Guo, Tito Fojo, Lawrence H. Schwartz, Binsheng Zhao, David Leung

    Publicado 2023
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  19. 19
    Clinical Characteristics and Course of 63 Patients with BRAF Mutant Lung Cancers

    Clinical Characteristics and Course of 63 Patients with BRAF Mutant Lung Cancers por Anya M. Litvak, Paul K. Paik, Kaitlin M. Woo, Camelia S. Sima, Matthew D. Hellmann, Maria E. Arcila, Marc Ladanyi, Charles M. Rudin, Mark G. Kris, Gregory J. Riely

    Publicado 2014
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  20. 20
    Safety of Programmed Death–1 Pathway Inhibitors Among Patients With Non–Small-Cell Lung Cancer and Preexisting Autoimmune Disorders

    Safety of Programmed Death–1 Pathway Inhibitors Among Patients With Non–Small-Cell Lung Cancer and Preexisting Autoimmune Disorders por Giulia C. Leonardi, Justin F. Gainor, Mehmet Altan, Sasha Kravets, Suzanne E. Dahlberg, Lydia Gedmintas, Roxana Azimi, Hira Rizvi, Jonathan W. Riess, Matthew D. Hellmann, Mark M. Awad

    Publicado 2018
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:

Ferramentas de procura: